Platinum Chemotherapy Combination
Showing 1 - 25 of >10,000
NSCLC Trial (Durvalumab, Tremelimumab, Pemetrexed)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Durvalumab
- +5 more
- (no location specified)
Aug 17, 2023
Non Small Cell Lung Cancer, Propranolol Trial (Propranolol HCl, Sintilimab, Chemotherapy)
Not yet recruiting
- Non Small Cell Lung Cancer
- Propranolol
- Propranolol hydrochloride
- +2 more
- (no location specified)
Jul 31, 2023
Metastatic Cervical Cancer Trial (Tislelizumab, Sitravatinib)
Not yet recruiting
- Metastatic Cervical Cancer
- (no location specified)
Jan 31, 2023
Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Urothelial Carcinoma Trial in Darlinghurst, Kogarah,
Terminated
- Advanced Solid Tumor
- +3 more
- NTX-301
- +2 more
-
Darlinghurst, New South Wales, Australia
- +1 more
Dec 18, 2022
Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer Trial (Durvalumab, Monalizumab, Carboplatin or Cisplatin)
Not yet recruiting
- Small Cell Lung Cancer
- +2 more
- Durvalumab
- +3 more
- (no location specified)
Jun 5, 2023
NSCLC (NSCLC) Trial (Ociperlimab, Placebo, Tislelizumab)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- Ociperlimab
- +8 more
- (no location specified)
Mar 17, 2023
Urothelial Carcinoma Associated 1 RNA, Human Trial (Pembrolizumab, Cisplatin, Carboplatin)
Active, not recruiting
- Urothelial Carcinoma Associated 1 RNA, Human
- Pembrolizumab
- +3 more
- (no location specified)
Aug 18, 2022
Mesothelioma Trial in Durham, Houston (Durvalumab / tremelimumab, Platinum cisplatin or carboplatin and pemetrexed chemo plus
Not yet recruiting
- Mesothelioma
- Durvalumab / tremelimumab
- Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
-
Durham, North Carolina
- +1 more
Jul 5, 2023
NSCLC Stage IV Trial in Gauting (combination regimen tremelimumab /durvalumab, platinum-based chemo (SoC))
Withdrawn
- NSCLC Stage IV
- combination regimen tremelimumab /durvalumab
- platinum-based chemotherapy (SoC)
-
Gauting, GermanyAsklepios Fachkliniken München-Gauting
Sep 26, 2022
Small Cell Lung Cancer Trial in Nice (acetazolamide in combination with platinum and etoposide-based radiochemo)
Recruiting
- Small Cell Lung Cancer
- acetazolamide in combination with platinum and etoposide-based radiochemotherapy
-
Nice, FranceCentre Antoine Lacassagne
Jan 19, 2023
Cholangiocarcinoma Trial in Birmingham (Novel combination of chemo and immunotherapy)
Recruiting
- Cholangiocarcinoma
- Novel combination of chemotherapy and immunotherapy
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Jul 28, 2022
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Australia (ATX-101 + Carboplatin + Pegylated
Recruiting
- Ovarian Cancer
- +3 more
- ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)
-
Blacktown, New South Wales, Australia
- +5 more
Nov 9, 2022
Ovarian Cancer Trial in Maywood (Decitabine, Carboplatin, Paclitaxel)
Not yet recruiting
- Ovarian Cancer
- Decitabine
- +3 more
-
Maywood, IllinoisLoyola University Medical Center
Aug 1, 2023
Urothelial Cancer Trial in Beijing (Atezolizumab, RO7247669, Tiragolumab)
Recruiting
- Urothelial Cancer
- Atezolizumab
- +2 more
-
Beijing, ChinaBeijing Cancer Hospital
Jan 18, 2023
Metastatic Esophageal Squamous Cell Carcinoma Trial in Qingdao (TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1
Recruiting
- Metastatic Esophageal Squamous Cell Carcinoma
- TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors(Sintilimab)
-
Qingdao, Shandong, China
- +1 more
Nov 13, 2023
Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal
Recruiting
- Platinum-Refractory Fallopian Tube Carcinoma
- +11 more
- Copanlisib Hydrochloride
- +4 more
-
Aurora, Colorado
- +2 more
Dec 8, 2022
Non Small Cell Lung Cancer Metastatic Trial (Pembrolizumab in Combination with Plinabulin and Docetaxel)
Not yet recruiting
- Non Small Cell Lung Cancer Metastatic
- Pembrolizumab in Combination with Plinabulin and Docetaxel
- (no location specified)
Oct 28, 2022
Neuroendocrine Tumors Trial (BI 764532, Carboplatin, Etoposide)
Not yet recruiting
- Neuroendocrine Neoplasms
- BI 764532
- +3 more
- (no location specified)
Nov 10, 2023
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed B-Cell Lymphoma Trial in Saint Louis (Mosunetuzumab,
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- +3 more
- Mosunetuzumab
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Jul 14, 2022
Carcinoma, Ovarian Epithelial Trial in Hidaka (pembrolizumab, olaparib, bevacizumab)
Recruiting
- Carcinoma, Ovarian Epithelial
- pembrolizumab
- +5 more
-
Hidaka, Saitama, JapanSaitama Medical Uiversity International Medical Center
Apr 25, 2022
Small Cell Lung Cancer Trial in New Haven (Combination immunotherapy with Ipilimumab and Nivolumab)
Active, not recruiting
- Small Cell Lung Cancer
- Combination immunotherapy with Ipilimumab and Nivolumab
-
New Haven, ConnecticutYale University, Yale Cancer Center
Apr 21, 2022
Esophageal Squamous Cell Carcinoma Trial in Nanjing (Sintilimab, Liposomal Paclitaxel + Cisplatin + S-1)
Active, not recruiting
- Esophageal Squamous Cell Carcinoma
- Sintilimab
- Liposomal Paclitaxel + Cisplatin + S-1
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Jul 16, 2022
Nasopharyngeal Carcinoma, Recurrent or Metastatic Nasopharyngeal Carcinoma Trial in Guangzhou (Toripalimab and Anlotinib)
Recruiting
- Nasopharyngeal Carcinoma
- Recurrent or Metastatic Nasopharyngeal Carcinoma
- Toripalimab and Anlotinib
-
Guangzhou, ChinaSun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
Mar 23, 2022